{"organizations": [], "uuid": "f8d7a8908c6853873ff0beb299426395a7b6188c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530592?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Series B round brings $55mm to RaNA Therapeutics", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Series B round brings $55mm to RaNA Therapeutics", "spam_score": 0.0, "site_type": "news", "published": "2015-07-28T02:40:00.000+03:00", "replies_count": 0, "uuid": "f8d7a8908c6853873ff0beb299426395a7b6188c"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530592?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Series B round brings $55mm to RaNA Therapeutics", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Series B round brings $55mm to RaNA Therapeutics Deal Date: Jul-01-2015 / Deal # 201530592 Executive Summary \nRaNA Therapeutics Inc. (developing RNA-targeted drugs that selectively activate protein expression in cells) raised $55mm in an oversubscribed Series B financing. MRL Ventures and the Baupost Group co-led and were joined by new buyers Rock Springs Capital, Brookside Capital, Leerink Partners, and a blue chip public investment fund, along with returning investors Atlas Venture, Monsanto , MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments, and SR One.", "external_links": [], "published": "2015-07-28T02:40:00.000+03:00", "crawled": "2015-07-28T14:38:06.982+03:00", "highlightTitle": ""}